All In Biotech

Drug Trial Radar · NCT02690207

Cross-vaccination Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK 1437173A) in Subjects Who Previously Received Placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) Studies.

Cross-vaccination Study of GSK Biologicals' Lyophilized Formulation of the Herpes Zoster Subunit (HZ/su) Vaccine (GSK 1437173A) in Subjects Who Previously Received Placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) Studies

Last checked: Nov 20, 2026Latest source record: Mar 4, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

8,687

Actual

Start

Mar 16, 2016

Primary completion

Mar 15, 2019

Study completion Mar 15, 2019

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Feb 24, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Prevention
Who can join
All sexes, from 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to cross-vaccinate and collect safety data in terms of unsolicited Adverse Events (AEs), Serious Adverse Events (SAEs) and potential Immune Mediated Disease (pIMD) from subjects \>= 50 Years of age (YOA) who previously received placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229).

Conditions

  • Herpes Zoster

Interventions

  • Herpes Zoster Vaccine GSK1437173ABiological

    Intramuscular injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)Time frame: During 30 days (Days 0-29) after any vaccination (across doses)
  2. Number of Subjects With Any and Related Serious Adverse Events (SAEs)Time frame: From Month 0 until study end (Month 14, i.e. 12 months post dose 2)
  3. Number of Subjects With Any and Related Potential Immune Mediated Diseases (pIMDs)Time frame: From Month 0 until study end (Month 14, i.e. 12 months post dose 2)

Locations

195 sites in 18 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Mesa, Arizona

  • GSK Investigational Site

    Phoenix, Arizona

  • GSK Investigational Site

    Phoenix, Arizona

  • GSK Investigational Site

    Phoenix, Arizona

  • GSK Investigational Site

    Tucson, Arizona

  • GSK Investigational Site

    Spring Valley, California

  • GSK Investigational Site

    Clearwater, Florida

  • GSK Investigational Site

    DeLand, Florida

  • GSK Investigational Site

    Jacksonville, Florida

  • GSK Investigational Site

    Jacksonville, Florida

  • GSK Investigational Site

    West Palm Beach, Florida

  • GSK Investigational Site

    Meridian, Idaho

  • GSK Investigational Site

    Wichita, Kansas

  • GSK Investigational Site

    Columbia, Maryland

  • GSK Investigational Site

    Elkridge, Maryland

  • GSK Investigational Site

    Kansas City, Missouri

  • GSK Investigational Site

    Las Vegas, Nevada

  • GSK Investigational Site

    Somers Point, New Jersey

  • GSK Investigational Site

    Cary, North Carolina

  • GSK Investigational Site

    Charlotte, North Carolina

  • GSK Investigational Site

    Hickory, North Carolina

  • GSK Investigational Site

    Salisbury, North Carolina

  • GSK Investigational Site

    Wilmington, North Carolina

  • GSK Investigational Site

    Winston-Salem, North Carolina

  • GSK Investigational Site

    Cleveland, Ohio

  • GSK Investigational Site

    Wadsworth, Ohio

  • GSK Investigational Site

    Pittsburgh, Pennsylvania

  • GSK Investigational Site

    Uniontown, Pennsylvania

  • GSK Investigational Site

    Greer, South Carolina

  • GSK Investigational Site

    Mt. Pleasant, South Carolina

  • GSK Investigational Site

    Bristol, Tennessee

  • GSK Investigational Site

    San Antonio, Texas

  • GSK Investigational Site

    Murray, Utah

  • GSK Investigational Site

    Newport News, Virginia

  • GSK Investigational Site

    Richmond, Virginia

  • GSK Investigational Site

    Winchester, Virginia

  • GSK Investigational Site

    Renton, Washington

  • GSK Investigational Site

    Maroubra, New South Wales, Australia

  • GSK Investigational Site

    Umina, New South Wales, Australia

  • GSK Investigational Site

    Westmead, New South Wales, Australia

Showing 40 of 195 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.